Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?

 
• By Derrick Gingery

EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.

US-EU cooperation
A lack of awareness of the PSA program for complex generics may be contributing to the lack of interest in it. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics